The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
Open accessAbstract
Summary: Background: SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion. Antibody against CD147 could block the infection of SARS-CoV-2. We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. Methods: All patients received recommended strategy from Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatments released by National Health Commission of China. Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5. Patients hospitalized in the same period were observed as concurrent control. The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test. This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245. Findings: 17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.005) and case severity (p=0.021) in patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.045, HR=0.374, 95%CI[0.143-0.978]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation: Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia. Funding: National Science and Technology Major Project.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Self-citationMiddle East Respiratory Syndrome
Arabi, Y. M., Balkhy, H. H., Hayden, F. G., Bouchama, A., Luke, T., Baillie, J. K., Al-Omari, A., Hajeer, A. H., Senga, M., Denison, M. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1408795 · Cited by 518
Cited by
COVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,016
Grant, M. C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E. L., & Wade, R. G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234765 · Cited by 649
Radzikowska, U., Ding, M., Tan, G., Zhakparov, D., Peng, Y., Wawrzyniak, P., Wang, M., Li, S., Morita, H., Altunbulakli, C., et al. (2020) · Allergy · doi:10.1111/all.14429 · Cited by 543
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Lythgoe, M. P., & Middleton, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 380
Simons, D., Shahab, L., Brown, J., & Perski, O. (2021) · Addiction · doi:10.1111/add.15276 · Cited by 371
Metadata
- Authors
- Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., Dong, K., Kang, W., Xia, J.-L., Miao, J.-L., Xie, R.-H., Wang, B., Sun, X.-X., Yang, X.-M., Lin, P., Geng, J.-J., Wang, K., Cui, H.-Y., Zhang, K., Chen, X.-C., Tang, H., Du, H., Yao, N., Liu, S.-S., Liu, L.-N., Zhang, Z., Gao, Z.-W., Nan, G., Wang, Q.-Y., Lian, J.-Q., Chen, Z.-N., & Zhu, P.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-03-24
- OpenAlex
- W3013997205
- Cited by
- 158
- References
- 2
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. https://app.cochat.ai/papers/10.1101/2020.03.21.20040691
- The paper
- Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., Dong, K., Kang, W., Xia, J.-L., Miao, J.-L., Xie, R.-H., Wang, B., Sun, X.-X., Yang, X.-M., Lin, P., Geng, J.-J., Wang, K., Cui, H.-Y., Zhang, K., . . . Zhu, P. (2020). Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv. https://doi.org/10.1101/2020.03.21.20040691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
